Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Greasley

Showing results (11-20 of 85) with videos related to

Pageof 9
Sort By:
Frontiers in Pharmacology|December 12, 2024
Kinetics of endothelin-1 and effect selective ET<sub>A</sub> antagonism on ET<sub>B</sub> activation: a mathematical modeling analysisK Melissa Hallow, Peter J Greasley, Hiddo J L Heerspink, et al.
Plos One|December 13, 2016
Deletion of Gpr55 Results in Subtle Effects on Energy Metabolism, Motor Activity and Thermal Pain SensationMikael Bjursell, Erik Ryberg, Tingting Wu, et al.
Diabetes, Obesity & Metabolism|October 13, 2017
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesisKaren M Hallow, Gabriel Helmlinger, Peter J Greasley, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 18, 2017
Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal FunctionSergei Petrykiv, C David Sjöström, Peter J Greasley, et al.
American Journal of Physiology. Renal Physiology|July 19, 2018
Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical dataK Melissa Hallow, Peter J Greasley, Gabriel Helmlinger, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 5, 2018
The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemiaGeoffrey A Block, David P Rosenbaum, Andrew Yan, et al.
Journal of Clinical Pharmacology|October 22, 2020
Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling AnalysisHongtao Yu, Weifeng Tang, Peter J Greasley, et al.
Clinical Pharmacology and Therapeutics|July 4, 2024
From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH TrialsAnne-Kristina Mercier, Sebastian Ueckert, Mikael Sunnåker, et al.
Diabetes, Obesity & Metabolism|October 13, 2025
Proteins and signalling pathways targeted by dapagliflozin and finerenone: Insights from DAPA-CKD and FIGARO-DKDMark André de la Rambelje, Adriaan A Voors, Peter J Greasley, et al.
Nature Cardiovascular Research|August 28, 2024
Current and future strategies for targeting the endothelin pathway in cardiovascular diseaseGeorge R Abraham, Thomas L Williams, Janet J Maguire, et al.
Pageof 9

Showing results (11-20 of 85) with videos related to

Sort By:
Pageof 9
Frontiers in Pharmacology|December 12, 2024
Kinetics of endothelin-1 and effect selective ET<sub>A</sub> antagonism on ET<sub>B</sub> activation: a mathematical modeling analysisK Melissa Hallow, Peter J Greasley, Hiddo J L Heerspink, et al.
Plos One|December 13, 2016
Deletion of Gpr55 Results in Subtle Effects on Energy Metabolism, Motor Activity and Thermal Pain SensationMikael Bjursell, Erik Ryberg, Tingting Wu, et al.
Diabetes, Obesity & Metabolism|October 13, 2017
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesisKaren M Hallow, Gabriel Helmlinger, Peter J Greasley, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 18, 2017
Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal FunctionSergei Petrykiv, C David Sjöström, Peter J Greasley, et al.
American Journal of Physiology. Renal Physiology|July 19, 2018
Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical dataK Melissa Hallow, Peter J Greasley, Gabriel Helmlinger, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 5, 2018
The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemiaGeoffrey A Block, David P Rosenbaum, Andrew Yan, et al.
Journal of Clinical Pharmacology|October 22, 2020
Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling AnalysisHongtao Yu, Weifeng Tang, Peter J Greasley, et al.
Clinical Pharmacology and Therapeutics|July 4, 2024
From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH TrialsAnne-Kristina Mercier, Sebastian Ueckert, Mikael Sunnåker, et al.
Diabetes, Obesity & Metabolism|October 13, 2025
Proteins and signalling pathways targeted by dapagliflozin and finerenone: Insights from DAPA-CKD and FIGARO-DKDMark André de la Rambelje, Adriaan A Voors, Peter J Greasley, et al.
Nature Cardiovascular Research|August 28, 2024
Current and future strategies for targeting the endothelin pathway in cardiovascular diseaseGeorge R Abraham, Thomas L Williams, Janet J Maguire, et al.
Pageof 9